

## OPEN

# MAIT cells are licensed through granzyme exchange to kill bacterially sensitized targets

A Kurioka<sup>1</sup>, JE Ussher<sup>1</sup>, C Cosgrove<sup>1</sup>, C Clough<sup>1</sup>, JR Fergusson<sup>1</sup>, K Smith<sup>1</sup>, Y-H Kang<sup>1</sup>, LJ Walker<sup>1</sup>, TH Hansen<sup>2</sup>, CB Willberg<sup>1,3</sup> and P Klenerman<sup>1,3</sup>

Mucosal-associated invariant T (MAIT) cells are an innate-like T-cell population restricted by the non-polymorphic, major histocompatibility complex class I-related protein 1, MR1. MAIT cells are activated by a broad range of bacteria through detection of riboflavin metabolites bound by MR1, but their direct cytolytic capacity upon recognition of cognate target cells remains unclear. We show that resting human MAIT cells are uniquely characterized by a lack of granzyme (Gr) B and low perforin expression, key granule proteins required for efficient cytotoxic activity, but high levels of expression of GrA and GrK. Bacterial activation of MAIT cells rapidly induced GrB and perforin, licensing these cells to kill their cognate target cells. Using a novel flow cytometry-based killing assay, we show that licensed MAIT cells, but not *ex vivo* MAIT cells from the same donors, can efficiently kill *Escherichia coli*-exposed B-cell lines in an MR1- and degranulation-dependent manner. Finally, we show that MAIT cells are highly proliferative in response to antigenic and cytokine stimulation, maintaining high expression of GrB, perforin, and GrA, but reduced expression of GrK following antigenic proliferation. The tightly regulated cytolytic capacity of MAIT cells may have an important role in the control of intracellular bacterial infections, such as *Mycobacterium tuberculosis*.

## INTRODUCTION

Mucosal-associated invariant T (MAIT) cells are an evolutionarily conserved sub-population of T cells in mammals, characterized by the expression of the semi-invariant V $\alpha$ 7.2-J $\alpha$ 33 chain of the T-cell receptor (TCR), which restricts them to the non-polymorphic, major histocompatibility complex class I-related protein 1, MR1.<sup>1–3</sup> In murine models, MAIT cells are critical for the control of *Bacillus Calmette-Guérin* (BCG),<sup>4</sup> *Klebsiella pneumoniae*<sup>5</sup> and *Francisella tularensis*<sup>6</sup> infections. Their broad reactivity to microbes has recently been attributed to their ability to recognize ligands bound to MR1 originating from metabolic intermediates of riboflavin.<sup>7</sup> MAIT cells are enriched in the intestine and liver, and represent 1–20% of CD8<sup>+</sup> T cells in the periphery in man.<sup>1,8–10</sup> In adult blood, MAIT cells are the dominant population among CD8<sup>+</sup> T cells that express the C-type lectin-like receptor CD161 at high levels.<sup>8,10,11</sup> These CD161<sup>++</sup> CD8<sup>+</sup> T cells are functionally and transcriptionally distinct from other CD8<sup>+</sup> T-cell populations,<sup>11,12</sup> with the

ability to respond to cytokines interleukin-12 (IL-12) and IL-18 in a TCR-independent manner.<sup>13</sup>

Previous studies into CD161<sup>++</sup>/MAIT cell effector functions have focused principally on their production of Tc1 and Tc17 cytokines.<sup>8,9,12–13</sup> Recently, MAIT cells were shown to kill epithelial cells infected by *Shigella dysenteriae*.<sup>14</sup> However, the factors regulating the cytotoxicity of MAIT cells and whether they can kill antigen-presenting cells (APCs), which in many infections provide a survival niche for intracellular bacteria, still remains to be addressed. This is a critical point, given their high frequencies in tissues, “effector-memory” phenotype<sup>11</sup> and cytotoxic potential; such activity must be tightly regulated in order to limit immunopathology.

The primary mechanism by which cytotoxic cells induce apoptosis in tumor or virus-infected cells is granule exocytosis. This is dependent upon granzymes gaining entry to the cytoplasm of the target cell through the action of perforin;<sup>15</sup> without perforin, internalized granzymes are retained in

<sup>1</sup>Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxford, Oxford, UK. <sup>2</sup>Department of Pathology and Immunology, Washington University School of Medicine, St Louis, Missouri, USA and <sup>3</sup>National Institute for Health Research Oxford Biomedical Research Centre, University of Oxford, Oxford, UK. Correspondence: A Kurioka (ayako.kurioka@ndm.ox.ac.uk)

Received 28 April 2014; accepted 26 July 2014; published online 1 October 2014. doi:10.1038/mi.2014.81

endosome-like vesicles, and do not induce apoptosis.<sup>16</sup> In humans, there are five granzymes with diverse substrate specificities: granzyme (Gr) A, GrB, GrH, GrK, and GrM. A hierarchy among these molecules determines cytotoxic efficiency, with perforin and GrB, but not GrA or GrK, correlating with lytic ability.<sup>17–20</sup> Instead, recent studies have suggested that GrA and GrK are primarily non-cytotoxic molecules promoting proinflammatory responses.<sup>21–23</sup> Perforin and GrB can be upregulated upon activation and proliferation,<sup>17,24</sup> and are regulated by transcription factors such as T-bet and Blimp1.<sup>25,26</sup>

In this study, we have performed a comprehensive characterization of the cytotoxicity of CD161<sup>++</sup>CD8<sup>+</sup> T cells, including the MAIT cells, and probe the relative contribution of TCR and innate cytokine signals regulating their granule content. Furthermore, we show that MAIT cells are highly proliferative *in vitro* and rapidly acquire high expression of GrB, GrA, and perforin. This cytotoxic phenotype “licenses” them to specifically kill target cells in an MR1-dependent manner.

## RESULTS

### Resting blood-derived human MAIT cells have a unique cytotoxic profile

First, we confirmed our previous finding<sup>12</sup> that *ex vivo*, peripheral blood CD161<sup>++</sup>CD8<sup>+</sup> T cells expressed almost no GrB ( $3.1 \pm 0.9\%$ ) compared with either CD161<sup>+</sup> (47.6%,  $P < 0.0001$ ) or CD161<sup>−</sup> sub-populations (18.5%,  $P < 0.01$ ; **Figure 1a**). The amount of perforin expressed by these cells, as measured by geometric mean fluorescence intensity, was also significantly lower than other CD8<sup>+</sup> T-cell sub-populations (both  $P < 0.0001$ ). In contrast, CD161<sup>++</sup>CD8<sup>+</sup> T cells expressed high levels of GrA ( $96.6 \pm 1.2\%$ ) compared with CD161<sup>+</sup> (87.2%,  $P < 0.05$ ) and CD161<sup>−</sup>CD8<sup>+</sup> T cells (31.3%,  $P < 0.0001$ ). CD161<sup>++</sup>CD8<sup>+</sup> T cells also uniquely expressed high levels of GrK ( $91.1 \pm 1.2\%$ ) compared with CD161<sup>+</sup>CD8<sup>+</sup> T cells (32.9%,  $P < 0.0001$ ) and CD161<sup>−</sup>CD8<sup>+</sup> T cells (16.3%,  $P < 0.0001$ ). Consistent with transcriptional profiling,<sup>11</sup> cord blood CD161<sup>++</sup>CD8<sup>+</sup> T cells were also GrA<sup>+</sup>GrK<sup>+</sup> (**Supplementary Figure S1A** online), suggesting this is an inherent feature of this subset.

Next, we asked whether this cytotoxic profile was characteristic of MAIT cells, or of the CD161<sup>++</sup>CD8<sup>+</sup> T-cell population as a whole. T cells possessing the V $\alpha$ 7.2 TCR within the CD161<sup>++</sup>CD8<sup>+</sup> T-cell population are defined as MAIT cells throughout this study (**Figure 1b**). Within CD161<sup>++</sup>CD8<sup>+</sup> T cells, there was no difference in expression of GrA and perforin between V $\alpha$ 7.2<sup>+</sup> cells and V $\alpha$ 7.2<sup>−</sup>. However, GrB expression was significantly lower ( $P < 0.05$ ) and GrK expression was significantly higher ( $P < 0.001$ ) in the V $\alpha$ 7.2<sup>+</sup> MAIT cells (**Figure 1c**). Analysis of the simultaneous expression of perforin and granzymes in MAIT cells confirmed that the majority of the population coexpressed GrA and GrK, whereas a mean of 30% of MAIT cells coexpressed GrA, GrK, and perforin (**Supplementary Figure S1B and C**).

Using ImageStream technology, GrA was seen to colocalize with CD107 $\alpha$ , a marker of cytotoxic granules, as well as with


GrK in CD161<sup>++</sup>CD8<sup>+</sup> T cells (**Figure 1d**), suggesting that GrA and GrK are preformed within lytic granules. Thus, CD161<sup>++</sup>CD8<sup>+</sup> T cells, including the MAIT cells, have the potential to release GrA, GrK, and perforin immediately upon target cell interaction.

### Physiologic stimulation via MR1 leads to degranulation and changes in cytotoxic profile of MAIT cells

We next investigated the regulation of cytotoxic potential in an *in vitro* model of MAIT cell activation. We have recently shown that MAIT cells can be activated both through the cognate interaction between MR1 and the TCR, as well as through IL-12 and IL-18 stimulation in a TCR-independent manner.<sup>13</sup> Therefore, we tested if either pathway, or a combination of these signals, could induce a cytotoxic phenotype within MAIT cells.

Using our previously described model,<sup>13</sup> THP1 cell lines were pre-exposed to paraformaldehyde (PFA)-fixed *Escherichia coli*, and then cultured with enriched CD8<sup>+</sup> T cells overnight, after which the cytotoxic profile of MAIT cells was evaluated (**Figure 2**). MAIT cells degranulated extensively in response to *E. coli* as measured by CD107 $\alpha$  expression (**Figure 2a**; 66.3%,  $P < 0.0001$ ). This was almost completely blocked by an anti-MR1-blocking antibody (20.9%;  $P < 0.0001$ ), whereas blocking IL-12 or IL-18 had minimal effect on the degranulation of the cells.

We then examined whether the expression of the key cytotoxic effector molecules, GrB and perforin, is modified by activation in this model. The frequency of MAIT cells expressing GrB increased to  $\sim 35\%$  in response to *E. coli* ( $P < 0.0001$ ; **Figure 2b**). Importantly, the addition of either anti-MR1-blocking antibody, or anti-IL-12-blocking antibody, significantly reduced the induction of GrB (6.5%,  $P < 0.001$ ; 12.2%,  $P < 0.001$ , respectively), and the combination of anti-MR1, anti-IL-12, and anti-IL-18-blocking antibodies inhibited GrB upregulation completely (2.28%,  $P < 0.001$ ). Confirming the need for a TCR signal, direct stimulation of MAIT cells with anti-CD3/CD28/CD2 beads, but not with anti-CD3 beads or cytokines alone, also led to significant upregulation of GrB (**Supplementary Figure S2A**). This suggests that TCR signals are necessary for GrB upregulation in response to *E. coli*, and that costimulation either with IL-12 or CD2/CD28 is also required. Of note, there was a dose-dependent increase of GrB expression with increasing concentrations of *E. coli* (**Supplementary Figure S3A and B**). At the highest BpC, however, there was no further increase in GrB expression, although these cells were maximally activated as measured by CD69 expression (**Supplementary Figure S3A**). This may be due to the downregulation of the TCR upon exposure to high doses of bacteria, as shown by V $\alpha$ 7.2 downregulation, in turn limiting further TCR-mediated upregulation of GrB. There was a loss of the CD161<sup>++</sup> population with increasing doses of *E. coli* as previously described,<sup>27</sup> but there was no visible loss of CD161 expression from the maximally activated MAIT cells (**Supplementary Figure S3A**). There was no difference in the frequency of MAIT cells or other CD8<sup>+</sup> T-cell populations when the cells were stained extracellularly or intracellularly for CD161 after activation (data not shown). Therefore, in this



**Figure 1** Resting blood-derived human mucosal-associated invariant T (MAIT) cells have a unique cytotoxic profile. (a) Expression of granzyme (Gr) B, perforin, GrA, and GrK in peripheral blood CD8<sup>+</sup> T cells from healthy donors according to CD161 expression levels. For each marker, representative staining gated on CD8<sup>+</sup> T cells (left), representative staining gated on CD161<sup>++</sup>, CD161<sup>+</sup>, and CD161<sup>-</sup> CD8<sup>+</sup> T cells (middle), and cumulative data for 12–15 healthy individuals (right) are shown. Results shown as mean  $\pm$  s.e.m., analyzed by repeated-measures one-way analysis of variance (ANOVA), with Bonferroni's multiple comparisons test. \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ , \*\*\*\* $P < 0.0001$ . (b) CD161<sup>++</sup> CD8<sup>+</sup> T cells are predominantly Vα7.2<sup>+</sup>, compared with CD161<sup>+</sup> and CD161<sup>-</sup> CD8<sup>+</sup> T cells. Representative staining of Vα7.2 T-cell receptor (TCR) on CD8<sup>+</sup> T cells according to CD161 expression levels and cumulative data are shown ( $n = 8$ ). (c) Expression of GrB, perforin, GrA, and GrK in Vα7.2<sup>+</sup> and Vα7.2<sup>-</sup> cells, gated within the CD161<sup>++</sup> CD8<sup>+</sup> T-cell population. Cumulative data are shown, analyzed by paired  $t$ -test ( $n = 8–12$ ). (d) Representative images showing Imagestream analysis of colocalization of GrA, GrK, and CD107α expression within CD161<sup>++</sup> CD8<sup>+</sup> T cells. Histograms of normalized cell frequency against colocalization as measured by Bright Detail Similarity scores;  $> 2.0$  is defined as colocalized (see **Supplementary Methods**).

activation model, we do not observe CD161 downregulation in MAIT cells.

We also observed perforin to be upregulated in this coculture model (20.8% vs. 66.7%,  $P < 0.0001$ ; **Figure 2c**). However, unlike GrB, perforin upregulation could not be blocked by the addition of the MR1-blocking antibody. IL-12-blocking

antibody also had only a small effect on the upregulation of perforin (66.7% vs. 54.3%,  $P < 0.01$ ). Therefore, multiple factors may be contributing to perforin upregulation; indeed, direct stimulation of MAIT cells with IL-7, IL-15, or IL-2 upregulated perforin (**Supplementary Figure S2B**). This contrasts with the TCR- and costimulation-dependent GrB upregulation





MAIT cells expressing GrK, and to a limited extent, GrA, although this did not reach significance (**Supplementary Figure S2C and D**). There was also no significant increase in GrA or GrK expression as measured by geometric mean fluorescence intensity when cells were directly stimulated with cytokines, such as IL-12 + IL-18. Furthermore, there was no significant upregulation of granzysin or FasL when MAIT cells were stimulated with anti-CD3/CD28/CD2 beads or *E. coli* (**Supplementary Figure S2E and F**). Thus, MAIT cells modify their granule contents upon physiological activation.

### Licensed MAIT cells can kill target cells in an MR1-dependent manner

MAIT cells are activated by a broad range of bacteria through recognition of their ligand, a metabolic precursor of riboflavin, presented by MR1.<sup>7</sup> Whether this recognition leads to cytotoxicity, and what mechanisms are involved, have not been probed in detail. Furthermore, when administered to target cells, GrA and GrK, expressed by resting MAIT cells, have been suggested not to induce apoptosis, while GrB, not expressed by resting MAIT cells, induces apoptosis at equivalent concentrations.<sup>21,34</sup>

To test the capacity of *ex vivo* MAIT cells to kill target cells, a flow cytometry-based killing assay was developed, based on the published FATAL assay.<sup>28</sup> Briefly, Epstein–Barr virus-transformed B-cell lines (BCLs) were either incubated with PFA-fixed *E. coli* or sterility control overnight and stained with carboxyfluorescein succinimidyl ester (CFSE) and CellTrace Violet (CTV) dyes, respectively. These were mixed at a 1:1 ratio and cocultured with enriched CD8<sup>+</sup> T cells at various E:T ratios. Specific killing of CFSE<sup>+</sup> target cells, but not CTV<sup>+</sup> control cells, was then calculated based on the ratio of CFSE<sup>+</sup> and CTV<sup>+</sup> cells in wells without effector cells. In addition, taking advantage of the capacity of modern flow cytometers to measure a greater number of parameters, CD107 $\alpha$  externalization by the CD161<sup>++</sup>CD8<sup>+</sup> T cells was measured. Therefore, by combining the FATAL assay with the LAMP-1 assay<sup>29</sup> and phenotyping the effector cells, our assay allows the identification of the cell population responsible for cytotoxicity; thus, removing the necessity to sort enrich specific or rare effector populations. The gating strategy is shown in **Supplementary Figure S4A**. Using this modified FATAL assay, we found that resting MAIT cells only killed 30% of *E. coli*-exposed BCLs even the highest E:T ratios, in an MR1-dependent manner (**Figure 3a and b**).

Next, we asked whether pre-activation of MAIT cells, eliciting a more cytotoxic phenotype, would enhance their cytotoxic capacity. Peripheral blood mononuclear cells (PBMCs) isolated from the same donors were either pre-stimulated with PFA-fixed *E. coli* for 6 days (licensed) or freshly thawed (*ex vivo*); both were enriched for CD8<sup>+</sup> T cells in parallel. Licensed MAIT cells were significantly more cytotoxic compared with *ex vivo* MAIT cells, killing up to 70% of *E. coli*-exposed BCLs ( $P < 0.0001$ ; **Figure 3c and d**). The frequency of CD161<sup>++</sup>CD8<sup>+</sup> T cells did not significantly differ between *ex vivo* and licensed cells (**Supplementary Figure S4B**), and

indeed *post hoc* adjustment of the E:T to the actual ratio of CD161<sup>++</sup>CD8<sup>+</sup> T cells to target cells showed licensed MAIT cells were more cytotoxic on a per cell basis (**Supplementary Figure S4C**). Target cell killing by the *E. coli*-stimulated CD8<sup>+</sup> T cells was abolished with the addition of the anti-MR1-blocking antibody, confirming MAIT cells were mediating the killing (**Figure 3e**). Inhibition of degranulation and perforin polymerization with ethylene glycol tetra-acetic acid also prevented killing, suggesting this process was degranulation mediated. Blocking FasL did not affect this killing, consistent with the low FasL expression on activated MAIT cells (**Supplementary Figure S2F**).


In addition, we confirmed that the CD161<sup>++</sup>CD8<sup>+</sup> T-cell population was responsible for target cell killing as only this CD8<sup>+</sup> T-cell population degranulated in response to *E. coli*-exposed BCLs (**Figure 3f and g**). Furthermore, this novel cytotoxicity assay uses two amine-reactive dyes that bind to both cytosolic and membrane proteins, which are less prone to dye transfer than the lipophilic dye used in the original FATAL assay; thus, we were able to measure trogocytosis of the target cell membrane by the T cells, indicating prior synapse formation.<sup>30</sup> This showed that CD161<sup>++</sup>CD8<sup>+</sup> T cells made immunological synapses with the CFSE<sup>+</sup> target cells, and not with the CTV<sup>+</sup> control cells (**Figure 3g and Supplementary Figure S3D**). *Ex vivo* CD161<sup>++</sup>CD8<sup>+</sup> T cells degranulated more readily than *E. coli*-stimulated CD161<sup>++</sup>CD8<sup>+</sup> T cells in response to the same target cells (**Figure 3f**), yet were less cytotoxic than the latter, consistent with the hypothesis that MAIT cells needed licensing by granzyme exchange to become highly cytotoxic. When CD107 $\alpha$ <sup>+</sup> cells within CD161<sup>++</sup>CD8<sup>+</sup> T cells were compared, the frequency of cells that had acquired CFSE was significantly higher in the *E. coli*-stimulated cells than in *ex vivo* cells (**Figure 3h**), suggesting there is also increased synapse formation between the target cells and *E. coli*-stimulated CD161<sup>++</sup>CD8<sup>+</sup> T cells compared with *ex vivo* CD161<sup>++</sup>CD8<sup>+</sup> T cells.

Overall, these data suggest that *E. coli*-stimulated, licensed MAIT cells maintain the capacity to degranulate and possess enhanced killing capacity compared with *ex vivo* MAIT cells.


### Rapid GrB upregulation in MAIT cells is associated with Blimp1 and T-bet expression

Next, we probed the kinetics of this MAIT cell licensing by examining GrB and perforin upregulation in response to *E. coli*. MAIT cells showed no change in the expression of GrB and perforin within the first 6 h of stimulation (**Figure 4a and b**), but markedly upregulated these effector molecules by 18 h, with most cells expressing GrB and perforin by 30 h. This upregulation was specific to the MAIT cell population, the kinetics of which was similar to anti-CD3/CD28/CD2 stimulation (**Figure 4c and d**).

The transcription factors T-bet and Blimp1 are both important for GrB expression in CD8<sup>+</sup> T cells.<sup>25,26</sup> To investigate whether these transcription factors are associated with GrB upregulation in MAIT cells, PBMCs were stimulated with *E. coli* for 24 h, with or without the addition of MR1- and IL-12-



**Figure 3** *E. coli*-stimulated mucosal-associated invariant T (MAIT) cells can efficiently kill target cells in an MR1- and degranulation-dependent manner. B-cell lines (BCLs) were either incubated with paraformaldehyde (PFA)-fixed *E. coli* or sterility control and stained with carboxyfluorescein succinimidyl ester (CFSE) and CellTrace Violet (CTV) dyes, respectively, and cocultured with enriched CD8 $^{+}$  T cells. **(a)** Percentage of specific killing of target BCLs by *ex vivo* MAIT cells at various E:T ratios. Mean  $\pm$  s.e.m. of duplicate results of three independent experiments shown ( $n = 10$ ). **(b)** Percentage of specific killing of target cells by *ex vivo* MAIT cells with and without an anti-MR1-blocking antibody at E:T = 50:1. ( $n = 9$ ). **(c)** Example plots showing the frequency of live *E. coli*-exposed BCLs and negative control BCLs without effector cells (left), with *ex vivo* MAIT cells (middle), or with MAIT cells stimulated with *E. coli* for 6 days (right), added at E:T = 10:1. **(d)** Percentage of specific killing of target cells by *ex vivo* and *E. coli*-stimulated MAIT cells from the same donors at E:T = 10:1. Mean  $\pm$  s.e.m. of duplicate results of three independent experiments are shown. ( $n = 8$ ). **(e)** Inhibition of killing at E:T = 10:1 by *E. coli*-stimulated MAIT cells in presence of anti-MR1 antibody, ethylene glycol tetra-acetic acid (EGTA), or anti-FasL antibody, compared with killing with no inhibitor. Repeated-measures one-way analysis of variance (ANOVA), with Bonferroni's multiple comparisons test. ( $n = 5$ ) **(f)** Cumulative data showing increase in %CD107 $\alpha$  $^{+}$  cells in indicated CD8 $^{+}$  T-cell populations compared with wells with T cells only. Analyzed by two-way ANOVA, comparing increase in CD107 $\alpha$  $^{+}$  expressing cells when target cells are added, within each CD8 $^{+}$  T-cell population, with Bonferroni's multiple comparisons test. CFSE $^{+}$  *E. coli*-exposed BCL = Target cells, CTV $^{+}$  negative control BCL = Neg cells. ( $n = 8$ ). **(g)** Representative plots of *ex vivo* and *E. coli*-stimulated CD8 T cells from the killing assays. Histograms showing expression of CD107 $\alpha$ , and CFSE and CTV acquired through trogocytosis in CD161 $^{++}$  CD8 $^{+}$  T cells. **(h)** Trogocytosis of CFSE from *E. coli*-exposed BCL membranes onto degranulating CD161 $^{++}$  CD8 $^{+}$  T cells ( $n = 8$ ). Analyzed by two-way ANOVA, comparing wells with *ex vivo* and *E. coli*-stimulated cells, with Bonferroni's multiple comparisons test. NS, nonsignificant. \* $P < 0.05$ , \*\*\* $P < 0.001$ , \*\*\*\* $P < 0.0001$ .




**Figure 4** Granzyme (Gr) B and perforin upregulation in *E. coli*-stimulated mucosal-associated invariant T (MAIT) cells is rapid and associated with Blimp1 and T-bet expression. (**a–d**) Peripheral blood mononuclear cells (PBMCs) were stimulated with (**a, b**) paraformaldehyde (PFA)-fixed *E. coli*, or (**c, d**) anti-CD3/CD28/CD2 coated beads, and stained for GrB and perforin at the indicated time points ( $n=3$ ). Asterisks (\*) indicate significant increases in effector molecules in MAIT cells compared with the unstimulated controls, by a two-way analysis of variance (ANOVA), with Bonferroni's multiple comparisons test. (**e–i**) PBMCs were stimulated with PFA-fixed *E. coli* for 24 h with and without blocking antibodies to MR1 and interleukin (IL)-12, and stained for GrB, T-bet, and Blimp1 ( $n=7$ ). (**e**) Cumulative data for frequency of GrB expressing MAIT cells and (**f**) representative example of GrB expression in MAIT cells after *E. coli* stimulation,  $\pm$  blocking antibodies to MR1 or IL-12. One-way ANOVA, Bonferroni's multiple comparisons test. (**g**) Representative T-bet and Blimp1 expression in MAIT cells unstimulated or stimulated with PFA-fixed *E. coli*  $\pm$  blocking antibodies to MR1 or IL-12. For figure legend, see panel f. (**h**) Frequency of GrB-expressing cells in T-bet<sup>+</sup> or T-bet<sup>-</sup> MAIT cells. (**i**) Frequency of GrB-expressing cells in Blimp1<sup>+</sup> or Blimp1<sup>-</sup> MAIT cells. Results analyzed by two-way ANOVA with Bonferroni's multiple comparisons test. Bars indicate mean  $\pm$  s.e.m. \* $P<0.05$ , \*\* $P<0.01$ , \*\*\* $P<0.001$ , \*\*\*\* $P<0.0001$ .

blocking antibodies. As expected from the THP1 coculture model (Figure 2), MAIT cells stimulated with *E. coli* upregulated GrB (Figure 4e and f), but also coexpressed T-bet and Blimp1 in an MR1- and IL-12-dependent manner (Figure 4g). Cells expressing T-bet or Blimp1 were more likely to express GrB (Figure 4h and i), supporting a role for these transcription factors in the upregulation of GrB in MAIT cells.

#### MAIT cells readily proliferate in response to *E. coli* and maintain a highly cytotoxic profile

Finally, we asked whether the granule content of MAIT cells were sustained during proliferation. When CTV-labeled PBMCs were cultured with PFA-fixed *E. coli* for 6 days, MAIT cells proliferated in a dose-dependent manner to *E. coli* (Figure 5a and b). The proliferation of MAIT cells was



**Figure 5** Mucosal-associated invariant T (MAIT) cells are readily proliferative in response to *E. coli* and maintain a highly cytotoxic profile. Peripheral blood mononuclear cells (PBMCs) from healthy donors were CellTrace Violet (CTV)-labeled and cultured with paraformaldehyde (PFA)-fixed *E. coli* for 6 days. BpC = bacteria per cell ratio. **(a)** Representative plot showing dilution of CTV against CD161 expression (upper panel) and Vα7.2 expression (lower panel) at 10 BpC or with anti-CD3/CD28/CD2 beads, gated on CD8<sup>+</sup> T cells. **(b)** Cumulative data (left) and representative flow cytometry histograms are shown for each BpC. One-way analysis of variance (ANOVA), with Bonferroni's multiple comparisons test. **(c)** Representative plot (left) and cumulative data (right) showing Ki67 staining in CD8<sup>+</sup> T cells after *E. coli*-stimulation at 10 BpC ( $n=4$ ). **(d)** Proliferation of Vα7.2<sup>+</sup>CD161<sup>+</sup>CD8<sup>+</sup> T cells in response to *E. coli* with anti-MR1, interleukin (IL)-12, and IL-18-blocking antibodies at the indicated BpCs. Results pooled from two independent experiments and analyzed by two-way ANOVA, with Bonferroni's multiple comparisons test. **(e)** GrB and perforin, and **(f)** GrA and GrK expression in CTV-labeled Vα7.2<sup>+</sup>CD161<sup>+</sup>CD8<sup>+</sup> T cells following *E. coli*-stimulation for 6 days. Cumulative data (left) and representative staining is shown (right). Gating for granzymes and perforin based on isotype controls. Results analyzed by paired *t*-test ( $n=8$ ). Bars indicate mean  $\pm$  s.e.m. \* $P<0.05$ , \*\* $P<0.01$ , \*\*\* $P<0.001$ , \*\*\*\* $P<0.0001$ .

confirmed by Ki67 staining (Figure 5c), and was inducible when enriched CD8<sup>+</sup> T cells were directly stimulated with *E. coli*-exposed THP1 cells (Supplementary Figure S5A), confirming this is a specific effect and not bystander proliferation. Interestingly, although most cells remained CD161<sup>+</sup> (Figure 5a, Supplementary Figure S5A), CD161 was

downregulated on MAIT cells with increasing rounds of cell divisions (Supplementary Figure S5B). In addition, although both CD8αα and CD8αβ subsets of MAIT cells proliferated, there was greater proliferation of the CD8αβ subset (Supplementary Figure S5C). To investigate the relative contributions of the TCR signal and innate cytokines for MAIT



cell proliferation, blocking antibodies to MR1 or IL-12 and IL-18 were added. Addition of the MR1-blocking antibody, but not IL-12- or IL-18-blocking antibodies, significantly inhibited MAIT cell proliferation (**Figure 5d**), demonstrating that *E. coli*-induced MAIT cell expansion is largely TCR dependent; this was further confirmed with enriched CD8<sup>+</sup> T cells (**Supplementary Figure S5A**). Of note, proliferation of MAIT cells at 10BpC could not be completely inhibited by the anti-MR1-blocking antibody, suggesting that other cytokines may be contributing to their proliferation. Indeed, CD161<sup>++</sup> CD8<sup>+</sup> T cells readily proliferated in response to IL-2, IL-15, or IL-12 in the absence of exogenous TCR stimulation (**Supplementary Figure S4D–G**).

We next probed how the cytotoxic profile of MAIT cells changed as they proliferated. PFA-fixed *E. coli* were added to CTV-stained PBMCs, and after 6 days GrB, perforin, GrK, and GrA expression was assessed. MAIT cells cultured with *E. coli* acquired a highly cytotoxic profile; ~100% of cells expressed GrB and ~90% of cells expressed perforin. GrB and perforin expression did not require proliferation, as CTV<sup>high</sup>, non-proliferating cells also expressed high levels of both cytotoxic mediators (**Figure 5e**). Although resting MAIT cells all express GrA, stimulated MAIT cells upregulated GrA as measured by geometric mean fluorescence intensity (**Figure 5f**). In turn, there was a significant loss of GrK expression by activated MAIT cells (**Figure 5f**).

Therefore, MAIT cells are highly proliferative to antigenic and cytokine stimuli *in vitro*, and antigenic stimulation, irrespective of proliferation, is associated with increased expression of perforin, GrB, and GrA, and decreased expression of GrK.

## DISCUSSION

In this article, we demonstrate that the unique cytotoxic granule content of resting MAIT cells changes markedly upon activation, licensing these cells to kill target cells with greater efficiency. Importantly, to our knowledge this is the first study to investigate the regulation of MAIT cell cytotoxicity and their ability to kill APCs. Our findings support a role for MAIT cells in the control of intracellular bacterial infection.

At rest, almost all CD161<sup>++</sup> CD8<sup>+</sup> T cells, including MAIT cells, express GrA and GrK within cytotoxic granules and, therefore, are poised to release these immediately upon degranulation. In contrast, they express low levels of perforin, no GrB, and little granzyme or FasL (**Supplementary Figure S2E and F**). GrA and GrK are closely related trypsin-like serine proteases<sup>15</sup> originally believed to function as pro-apoptotic proteases,<sup>31–33</sup> however, recent studies have suggested that they are inefficient inducers of cell death.<sup>21,22,34</sup> Human GrA is significantly less cytotoxic than mouse GrA,<sup>35,36</sup> and in virus-specific CD8<sup>+</sup> T cells, cytotoxicity inversely correlated with GrK expression, whereas GrA expression did not correlate with lytic ability.<sup>17</sup> Instead, GrA and GrK have been shown to activate monocytes to produce proinflammatory cytokines such as IL-1 $\beta$  and tumor necrosis factor- $\alpha$ .<sup>21–23,34</sup> Intriguingly, a recent paper by Wensink *et al.*<sup>37</sup> has demonstrated *in vivo* and

*in vitro* that GrK binds to Gram-negative bacteria and lipopolysaccharide, synergistically increasing lipopolysaccharide-induced release of proinflammatory cytokines. GrA release by  $\gamma\delta$  T cells is also critical in the control of BCG growth by inducing tumor necrosis factor- $\alpha$  production in infected macrophages,<sup>38</sup> and similarly, degranulation of resting MAIT cells may assist in the control of bacterial infection through phagocyte activation. Once GrA and GrK are released from the cell, the signals that may increase the production of these granzymes and aid the replenishment of the granules are unknown. Of note, direct stimulation of MAIT cells with various cytokines such as IL-12 + IL-18 did not significantly increase the amount of GrA or GrK expressed by *ex vivo* MAIT cells as measured by geometric mean fluorescence intensity, although IL-15 induced a slight increase in GrA in 6/10 donors (**Supplementary Figure S2C and D**).

Following antigen exposure, MAIT cells rapidly transition to a more classical cytotoxic cell type, displaying high levels of GrB and perforin. This is consistent with previous work showing that activated MAIT cells can secrete GrB,<sup>8</sup> and that GrB expression in CD8<sup>+</sup> T cells positively correlates with antigenic stimulation.<sup>17,39</sup> When we probed the mechanisms controlling the early upregulation of GrB by activated MAIT cells, we found this to be dependent upon engagement of the TCR with MR1 and IL-12 or costimulation through CD2/CD28. This is in contrast to degranulation, which is dependent solely on the interaction of the TCR with MR1, and perforin upregulation, which could be induced by multiple cytokines. Among the granzymes, GrB is the most potent, especially in humans where it induces apoptosis in a caspase-independent manner.<sup>15,40</sup> Thus, the requirement for a second signal for maximal expression of GrB in TCR-stimulated MAIT cells may be important to prevent unwanted tissue damage. The relative importance of MR1- and cytokine-mediated regulation of MAIT cell cytotoxicity *in vivo* will be crucial in harnessing the cytotoxic potential of these cells. Our data also suggest that the transcription factors Blimp1 and T-bet may be involved in this regulation of GrB expression in MAIT cells. In conventional CD8<sup>+</sup> T cells, T-bet and Blimp1 are independently regulated, with Blimp1 deficiency resulting in a failure to produce GrB.<sup>25,26</sup> Whether Blimp1 and T-bet has a similarly critical role in GrB expression in MAIT cells remains to be determined.

Highly cytotoxic, licensed MAIT cells were able to kill up to 70% of *E. coli*-exposed BCLs. Although both *ex vivo* and licensed MAIT cells degranulated upon exposure to target cells, *ex vivo* MAIT cells showed significantly less cytotoxicity compared with licensed MAIT cells, consistent with changes in granule content with activation. Blocking experiments showed killing by these licensed MAIT cells was dependent on TCR-mediated degranulation, and not Fas-mediated killing, which is important in invariant natural killer T-cell cytotoxicity.<sup>41</sup>

Interestingly, CD161<sup>++</sup> cells within the few CD8<sup>+</sup> T cells in the killing assays degranulated in response to *E. coli*, and indeed CD8<sup>+</sup> CD4<sup>+</sup> MAIT cells could be activated by *E. coli* as readily as CD8<sup>+</sup> MAIT cells (**Supplementary Figure S6**). Although we cannot rule out CD8 downregulation, conventional CD8<sup>+</sup>

T-cell responses also do not necessarily require, but can be augmented by, the CD8 coreceptor. In conventional CD8<sup>+</sup> T cells, CD8 coreceptor enhances the binding of the TCR to the peptide-major histocompatibility complex, and cytolytic responses may be abrogated when coreceptor binding is inhibited.<sup>42</sup> However, in the context of high-affinity agonist ligands, APCs expressing wild-type or CD8-null human leukocyte antigen molecules induces CD107 $\alpha$  externalization by CD8<sup>+</sup> T cells to a similar extent across a range of peptide concentrations, whereas abrogation of coreceptor binding inhibits degranulation in response to low-affinity peptide variants, even at high peptide concentrations.<sup>43</sup> Molecular analyses have shown that MR1 can accommodate a range of riboflavin-derived ligands with different binding affinities,<sup>10,44</sup> and given that murine MAIT cells are mostly CD8<sup>-</sup>,<sup>10</sup> the role of the CD8 coreceptor in MAIT cell cytotoxicity and biology is a question that warrants further investigation.

The ability of activated MAIT cells to kill target cells may have an important role in bacterial control *in vivo*. A recent paper showed that MAIT cells can kill epithelial cells infected with *S. flexneri*,<sup>14</sup> suggesting that this function may be important for preventing cytosolic bacteria from crossing the mucosal barrier. Other intracellular bacteria such as *Mycobacterium tuberculosis* can replicate in macrophages<sup>45</sup> and B cells,<sup>46</sup> surviving inside a segregated endosomal compartment. Efficient killing of infected APCs by MAIT cells may lead to enhanced clearance of such bacteria. Intriguingly, an *in vivo* model using BCG found that IL-12 rather than recognition of MR1 by murine MAIT cells was required for their control of BCG growth,<sup>4</sup> suggesting that degranulation was not critical in this model. Similarly, murine MAIT cell control of *F. tularensis* growth *in vitro* was mediated by cytokine production, not infected cell lysis.<sup>6</sup> Successful killing of infected cells will ultimately depend upon various factors including ligand availability for MR1 loading, inhibitors of cytolysis expressed by the infected cell,<sup>47,48</sup> and inhibitory/costimulatory signals. Indeed, we found that CD161 is a costimulatory molecule on MAIT cells, and its ligation induces a substantial increase in target cell killing (Fergusson *et al.*, in press,<sup>49</sup> and Smith *et al.*, unpublished data). Thus, whether cytotoxicity has a significant role in protection mediated by MAIT cells *in vivo* will most likely depend on both the pathogen and the infected host cell in question.

In this study, we also demonstrate that adult MAIT cells proliferate in response to cytokines as well as TCR stimulation. MAIT cell expansion could be induced through *E. coli* stimulation in an MR1-dependent manner, a property recently shown to be acquired during fetal development.<sup>50</sup> Interestingly, MAIT cells downregulated CD161 with increasing rounds of cell division (Supplementary Figure S5B), in agreement with previous observations that MAIT cell clones can be CD161<sup>-</sup>.<sup>3</sup> In our hands, we do not observe CD161 downregulation during short-term activation of MAIT cells (Supplementary Figure S3), as has been shown previously,<sup>51</sup> but as CD161 costimulates T-cell proliferation,<sup>52</sup> downregulation of CD161 with proliferation may be beneficial for the continued survival of the cells by limiting activation-induced cell death. In contrast

to previous studies,<sup>8,53</sup> a greater proportion of CD161<sup>++</sup> CD8<sup>+</sup> T cells, including the V $\alpha$ 7.2<sup>+</sup> MAIT cells, proliferated when stimulated with IL-2 or IL-15 compared with CD161<sup>+</sup> CD8<sup>+</sup> T cells, whereas phytohaemagglutinin induced limited proliferation despite high activation (Supplementary Figure S5C and D). Given the sensitivity of MAIT cells to activation-induced cell death,<sup>27,54</sup> MAIT cell proliferation most likely depends on a balance between expansion and activation-induced cell death, and may explain the variation between MAIT cell proliferation studies. *In vivo*, once MAIT cells are attracted to sites of infection/inflammation, their functional impact, including cytotoxic activity, may be further perpetuated by their proliferation.

Overall, our results show that MAIT cell cytotoxicity is suppressed in the resting state, but upon continued exposure to bacteria, they rapidly acquire a cytotoxic phenotype, licensing them to kill target cells. Maximum expression of GrB requires both TCR stimulation and a second signal, provided by IL-12 or costimulation, whereas perforin can be induced by multiple factors. Release of these cytotoxic mediators, however, is ultimately dependent on MR1. This tight regulation of MAIT cell cytotoxicity may have an important role in the control of intracellular bacterial infections, such as *M. tuberculosis*, while limiting immune-mediated pathology. Further elucidation of the relative role of MR1-dependent and cytokine-mediated regulation of MAIT cell function *in vivo* will be important in addressing this issue.

## METHODS

**Donors.** Healthy donors were laboratory volunteers and leukocyte cones (NHS Blood Services, Oxford, UK). Umbilical cord blood samples were provided by the NHS Blood Services. All subjects were recruited in agreement with the local ethics committees of all participating institutions. PBMCs were isolated using Lymphoprep (AxisShield, Oslo, Norway). Cells were thawed and washed in RPMI 1640 with 10% fetal calf serum, L-glutamine, and penicillin/streptomycin (all Sigma-Aldrich, Dorset, UK).

**Flow cytometry.** For immunofluorescence staining, dead cells were excluded with the Near-IR Dead-Cell stain (Invitrogen, Paisley, UK). Antibodies used were: anti-CD3 PE-Cy7 or APC, anti-CD8 PerCP-Cy5.5 or eFluor 450, anti-CD69 FITC (eBioscience, Hatfield, UK); anti-CD161 PE or APC, anti-CD4 VioGreen (Miltényi Biotec, Surrey, UK); anti-V $\alpha$ 7.2 PE or FITC or PE-Cy7, anti-CD107 $\alpha$  PE-Cy7, anti-GrA PerCP-Cy5.5, anti-Perforin Pacific Blue, anti-granulysin PE, anti-FasL PE (Biolegend, London, UK); anti-GrB AlexaFluor700, anti-Perforin FITC, anti-Ki67 FITC (BD Biosciences, Oxford, UK), anti-GrB APC (Invitrogen); anti-GrK FITC (Immunotools, Friesoythe, Germany); anti-T-bet PE (Santa Cruz Biotechnology, Heidelberg, Germany); anti-GrA FITC, anti-Blimp1 AlexaFluor488 (R&D Systems, Abingdon, UK); and anti-CD8 $\beta$  PE (Beckman Coulter, High Wycombe, UK).

Data were collected on the flow cytometers LSRII (BD Biosciences) or MACSQuant (Miltényi Biotec), and was analyzed using FlowJo v9.6 (TreeStar, Ashland, OR). For ImageStream analysis, see Supplementary Methods.

***In vitro* stimulation.** *E. coli* (DH5 $\alpha$ , Invitrogen) was fixed in 2% PFA for 20 min, and washed extensively. A sterility control was prepared in identical manner and used as a negative control. In coculture experiments, *E. coli*, or the negative control, was added to THP1 cells (ECACC, Wiltshire, UK) at 25 Bacteria-per-Cell (BpC) overnight. Subsequently, THP1 cells were washed and CD8<sup>+</sup> T cells isolated

using CD8 Microbeads (Miltenyi Biotec; purities were  $\geq 90\%$ ) and anti-CD107 $\alpha$  antibody were added to the wells overnight. For further details, see **Supplementary Methods**.

**Killing assays.** The assay was based on the FATAL assay.<sup>28</sup> BCLs were either coincubated with PFA-fixed *E. coli* at 25BpC or the negative control overnight. Cells were harvested and the *E. coli*-exposed BCLs were stained with CellTrace CFSE (CFSE; Invitrogen), whereas the negative control BCLs were stained with CTV (Invitrogen) according to the manufacturer's protocol. After extensive washing, the CFSE- and CTV-labeled cells were mixed at a 1:1 ratio before plating.

CD8<sup>+</sup> T cells were isolated from PBMCs using CD8 Microbeads (Miltenyi Biotec), and added to the wells at the indicated E:T ratios overnight, with an anti-CD107 $\alpha$  antibody. E:T indicates ratio of CD8<sup>+</sup> T cells to CFSE<sup>+</sup> target cells, unless otherwise indicated. CD8<sup>+</sup> T-cell purities were  $\geq 90\%$ . Experiments were done in duplicate. An MR1-blocking antibody (clone 26.5), a FasL-blocking antibody (clone NOK-1, BioLegend) or an appropriate isotype control was added at 5  $\mu\text{g ml}^{-1}$  for blocking experiments. To block degranulation, 5 mM ethylene glycol tetra-acetic acid (Sigma-Aldrich) with 1 mM MgCl<sub>2</sub> (Affymetrix, High Wycombe, UK) was used.

Following incubation, cells were stained with a live-dead maker (Invitrogen) before fixation/permeabilization for the staining of relevant markers. Gating is shown in **Supplementary Figure S4A**. Based on the %survival of CFSE<sup>+</sup> cells in wells containing no effectors (E:T = 0:1), the expected frequency of target cells can be found:

$$\text{Expected ratio (ER)} = \% \text{CFSE}^+ \text{ cells} / \% \text{CTV}^+ \text{ cells}$$

Using this ratio, the % specific killing can be calculated:

$$\% \text{ specific killing} = 100 \times [(\text{ER} \times \% \text{CTV}^+ \text{ cells}) - \% \text{CFSE}^+ \text{ cells}] / (\text{ER} \times \% \text{CTV}^+ \text{ cells})$$

For the *post hoc* estimation of the actual E:T ratio in each well, the frequency of CD161<sup>++</sup> CD8<sup>+</sup> T cells within live cells was divided by the expected frequency of CFSE<sup>+</sup> cells in each well ( $\text{ER} \times \% \text{CTV}^+ \text{ cells}$ ).

**Proliferation assays.** PBMCs were labeled with CTV (Invitrogen) according to the manufacturer's protocol, and cultured for 6 days with either PFA-fixed *E. coli* at the indicated BpC, or the sterility control. An MR1-blocking antibody (clone 26.5), IL-12p40/70-blocking antibody (eBioscience), IL-18-blocking antibody (clone 126-2H, MBL International, Woburn, MA) or an appropriate isotype control was used at 5  $\mu\text{g ml}^{-1}$  for blocking experiments. Alternatively, THP1 cells were cultured with *E. coli* at 25BpC overnight before irradiation and were cocultured with CTV-labeled CD8<sup>+</sup> T cells enriched with CD8 Microbeads for 6 days, with autologous irradiated feeder cells. For cytokine-induced proliferation, CTV-labeled PBMCs were cultured for 6 days with the following stimuli: recombinant human IL-2 (100 IU ml<sup>-1</sup>), IL-15 (25 ng ml<sup>-1</sup>), IL-18 (50 ng ml<sup>-1</sup>), IL-12 (50 ng ml<sup>-1</sup>), phytohaemagglutinin (2  $\mu\text{g ml}^{-1}$ ), anti-CD3-coated or anti-CD3/CD28/CD2-coated beads (Miltenyi Biotec) at a 1:1 ratio, or the indicated combinations.

**Statistical analysis.** All graphs and statistical analyses were completed using GraphPad Prism software Version 6.0b (La Jolla, CA). Coexpression analysis was performed with SPICE software Version 5.3.<sup>55</sup> Statistical significance was assessed using paired Student's *t*-test, repeated-measures one-way analysis of variances or two-way analysis of variances, with Bonferroni's correction for multiple comparison assays. All data presented as means with s.e.m., unless otherwise indicated.

**SUPPLEMENTARY MATERIAL** is linked to the online version of the paper at <http://www.nature.com/mi>

## ACKNOWLEDGMENTS

This work was supported by the Wellcome Trust (WT091663MA); the Medical Research Council; the NIHR Biomedical Research Centre (Oxford); the Nuffield Department of Clinical Medicine (Oxford); the James Martin School for the 21st Century (Oxford); the National Institutes of Health (NIAD 5U19A082630 and AI046553), and the Oxford Dominions Trust.

## DISCLOSURE

The authors declared no conflict of interest.

© 2015 Society for Mucosal Immunology

## REFERENCES

1. Treiner, E. *et al.* Selection of evolutionarily conserved mucosal-associated invariant T cells by MR1. *Nature* **422**, 164–169 (2003).
2. Le Bourhis, L. *et al.* Antimicrobial activity of mucosal-associated invariant T cells. *Nat. Immunol.* **11**, 701–708 (2010).
3. Gold, M.C. *et al.* Human mucosal associated invariant T cells detect bacterially infected cells. *PLoS Biol.* **8**, e1000407 (2010).
4. Chua, W.J. *et al.* Polyclonal mucosal-associated invariant T cells have unique innate functions in bacterial infection. *Infect. Immun.* **80**, 3256–3267 (2012).
5. Georgel, P., Radosavljevic, M., Macquin, C. & Bahram, S. The non-conventional MHC class I MR1 molecule controls infection by *Klebsiella pneumoniae* in mice. *Mol. Immunol.* **48**, 769–775 (2011).
6. Meierovics, A., Yankelevich, W.-J.C. & Cowley, S.C. MAIT cells are critical for optimal mucosal immune responses during *in vivo* pulmonary bacterial infection. *Proc. Natl. Acad. Sci. USA* **110**, E3119–E3128 (2013).
7. Kjer-Nielsen, L. *et al.* MR1 presents microbial vitamin B metabolites to MAIT cells. *Nature* **491**, 717–723 (2012).
8. Dusseaux, M. *et al.* Human MAIT cells are xenobiotic-resistant, tissue-targeted, CD161hi IL-17-secreting T cells. *Blood* **117**, 1250–1259 (2011).
9. Tang, X.-Z. *et al.* IL-7 licenses activation of human liver intrasinusoidal mucosal-associated invariant T cells. *J. Immunol.* **190**, 3142–3152 (2013).
10. Reantragoon, R. *et al.* Antigen-loaded MR1 tetramers define T cell receptor heterogeneity in mucosal-associated invariant T cells. *J. Exp. Med.* **210**, 2305–2320 (2013).
11. Walker, L.J. *et al.* Human MAIT and CD8 $\alpha\alpha$  cells develop from a pool of type-17 precommitted CD8<sup>+</sup> T cells. *Blood* **119**, 422–433 (2012).
12. Billerbeck, E. *et al.* Analysis of CD161 expression on human CD8<sup>+</sup> T cells defines a distinct functional subset with tissue-homing properties. *Proc. Natl. Acad. Sci. USA* **107**, 3006–3011 (2010).
13. Ussher, J.E. *et al.* CD161<sup>++</sup> CD8<sup>+</sup> T cells, including the MAIT cell subset, are specifically activated by IL-12 + IL-18 in a TCR-independent manner. *Eur. J. Immunol.* **44**, 195–203 (2014).
14. Le Bourhis, L. *et al.* MAIT cells detect and efficiently lyse bacterially-infected epithelial cells. *PLoS Pathog.* **9**, e1003681 (2013).
15. Chowdhury, D. & Lieberman, J. Death by a thousand cuts: granzyme pathways of programmed cell death. *Annu. Rev. Immunol.* **26**, 389–420 (2008).
16. Pinkoski, M.J. *et al.* Entry and trafficking of granzyme B in target cells during granzyme B-perforin-mediated apoptosis. *Blood* **92**, 1044–1054 (1998).
17. Harari, A., Enders, F.B., Cellerai, C., Bart, P.A. & Pantaleo, G. Distinct profiles of cytotoxic granules in memory CD8 T cells correlate with function, differentiation stage, and antigen exposure. *J. Virol.* **83**, 2862–2871 (2009).
18. Wolint, P., Betts, M.R., Koup, R.A. & Oxenius, A. Immediate cytotoxicity but not degranulation distinguishes effector and memory subsets of CD8<sup>+</sup> T cells. *J. Exp. Med.* **199**, 925–936 (2004).
19. Bratke, K., Kuepper, M., Bade, B., Virchow, J.C. & Luttmann, W. Differential expression of human granzymes A, B, and K in natural killer cells and during CD8<sup>+</sup> T cell differentiation in peripheral blood. *Eur. J. Immunol.* **35**, 2608–2616 (2005).
20. Curtsinger, J.M., Lins, D.C., Johnson, C.M. & Mescher, M.F. Signal 3 tolerant CD8 T cells degranulate in response to antigen but lack granzyme B to mediate cytotoxicity. *J. Immunol.* **175**, 4392–4399 (2005).
21. Metkar, S.S. *et al.* Human and mouse granzyme A induce a proinflammatory cytokine response. *Immunity* **29**, 720–733 (2008).
22. Cooper, D.M., Pechkovsky, D.V., Hackett, T.L., Knight, D.A. & Granville, D.J. Granzyme K activates protease-activated receptor-1. *PLoS One* **6**, e21484 (2011).



23. Sower, L.E. *et al.* Extracellular activities of human granzyme A. Monocyte activation by granzyme A versus alpha-thrombin. *J. Immunol.* **156**, 2585–2590 (1996).
24. Makedonas, G. *et al.* Rapid up-regulation and granule-independent transport of perforin to the immunological synapse define a novel mechanism of antigen-specific CD8<sup>+</sup> T cell cytotoxic activity. *J. Immunol.* **182**, 5560–5569 (2009).
25. Kallies, A., Xin, A., Belz, G.T. & Nutt, S.L. Blimp-1 transcription factor is required for the differentiation of effector CD8<sup>+</sup> T Cells and memory responses. *Immunity* **31**, 283–295 (2009).
26. Cruz-Guilloty, F. *et al.* Runx3 and T-box proteins cooperate to establish the transcriptional program of effector CTLs. *J. Exp. Med.* **206**, 51–59 (2009).
27. Cosgrove, C. *et al.* Early and nonreversible decrease of CD161<sup>+</sup> MAIT cells in HIV infection. *Blood* **121**, 951–961 (2013).
28. Sheehy, M.E., McDermott, A.B., Furlan, S.N., Klenerman, P. & Nixon, D.F. A novel technique for the fluorometric assessment of T lymphocyte antigen specific lysis. *J. Immunol. Methods* **249**, 99–110 (2001).
29. Betts, M.R. *et al.* Sensitive and viable identification of antigen-specific CD8<sup>+</sup> T cells by a flow cytometric assay for degranulation. *J. Immunol. Methods* **281**, 65–78 (2003).
30. Poupot, M., Fournié, J.-J. & Poupot, R. Troglucytosis and killing of IL-4-polarized monocytes by autologous NK cells. *J. Leukoc. Biol.* **84**, 1298–1305 (2008).
31. Jiang, W., Chai, N.R., Maric, D. & Bielekova, B. Unexpected role for granzyme K in CD56<sup>bright</sup> NK cell-mediated immunoregulation of multiple sclerosis. *J. Immunol.* **187**, 781–790 (2011).
32. Jenkins, M.R., Trapani, J.A., Doherty, P.C. & Turner, S.J. Granzyme K expressing cytotoxic T lymphocytes protects against influenza virus in granzyme AB<sup>-/-</sup> Mice. *Viral Immunol.* **21**, 341–346 (2008).
33. Zhao, T. *et al.* Granzyme K cleaves the nucleosome assembly protein SET to induce single-stranded DNA nicks of target cells. *Cell Death Differ.* **14**, 489–499 (2007).
34. Joeckel, L.T. *et al.* Mouse granzyme K has pro-inflammatory potential. *Cell Death Differ.* **18**, 1112–1119 (2011).
35. Kaiserman, D. *et al.* Identification of Serpinb6b as a species-specific mouse granzyme A inhibitor suggests functional divergence between human and mouse granzyme A. *J. Biol. Chem.* **289**, 9408–9417 (2014).
36. Susanto, O. *et al.* Mouse granzyme A induces a novel death with writhing morphology that is mechanistically distinct from granzyme B-induced apoptosis. *Cell Death Differ.* **20**, 1183–1193 (2013).
37. Wensink, A.C. *et al.* Granzyme K synergistically potentiates LPS-induced cytokine responses in human monocytes. *Proc. Natl. Acad. Sci. USA* **111**, 5974–5979 (2014).
38. Spencer, C.T. *et al.* Granzyme A produced by  $\gamma\delta$  T cells induces human macrophages to inhibit growth of an intracellular pathogen. *PLoS Pathog.* **9**, e1003119 (2013).
39. Migueles, S.A. *et al.* Lytic granule loading of CD8<sup>+</sup> T cells is required for HIV-infected cell elimination associated with immune control. *Immunity* **29**, 1009–1021 (2008).
40. Kaiserman, D. *et al.* The major human and mouse granzymes are structurally and functionally divergent. *J. Cell Biol.* **175**, 619–630 (2006).
41. Wingender, G., Krebs, P., Beutler, B. & Kronenberg, M. Antigen-specific cytotoxicity by invariant NKT cells in vivo is CD95/CD178-dependent and is correlated with antigenic potency. *J. Immunol.* **185**, 2721–2729 (2010).
42. Purbhoo, M.A. *et al.* The human CD8 coreceptor effects cytotoxic T cell activation and antigen sensitivity primarily by mediating complete phosphorylation of the T cell receptor chain  $\zeta$ . *J. Biol. Chem.* **276**, 32786–32792 (2001).
43. Laugel, B. *et al.* Different T cell receptor affinity thresholds and CD8 coreceptor dependence govern cytotoxic T lymphocyte activation and tetramer binding properties. *J. Biol. Chem.* **282**, 23799–23810 (2007).
44. López-Sagaseta, J. *et al.* MAIT recognition of a stimulatory bacterial antigen bound to MR1. *J. Immunol.* **191**, 5268–5277 (2013).
45. Buckner, M.M.C. & Finlay, B.B. Host-microbe interaction: innate immunity cues virulence. *Nature* **472**, 179–180 (2011).
46. Souwer, Y. *et al.* Selective infection of antigen-specific B lymphocytes by *Salmonella* mediates bacterial survival and systemic spreading of infection. *PLoS One* **7**, e50667 (2012).
47. Toossi, Z. *et al.* Induction of serine protease inhibitor 9 by *Mycobacterium tuberculosis* inhibits apoptosis and promotes survival of infected macrophages. *J. Infect. Dis.* **205**, 144–151 (2012).
48. Willberg, C.B. *et al.* Protection of hepatocytes from cytotoxic T cell mediated killing by interferon-alpha. *PLoS One* **2**, e791 (2007).
49. Fergusson, R.J. *et al.* CD161 defines a transcriptional and functional phenotype shared across distinct human T cell lineages. *Cell. Rep.* (in press).
50. Leeansyah, E., Loh, L., Nixon, D.F. & Sandberg, J.K. Acquisition of innate-like microbial reactivity in mucosal tissues during human fetal MAIT-cell development. *Nat. Commun.* **5**, 3143 (2014).
51. Leeansyah, E. *et al.* Activation, exhaustion, and persistent decline of the antimicrobial MR1-restricted MAIT-cell population in chronic HIV-1 infection. *Blood* **121**, 1124–1135 (2013).
52. Germain, C. *et al.* Induction of lectin-like transcript 1 (LLT1) protein cell surface expression by pathogens and interferon- $\gamma$  contributes to modulate immune responses. *J. Biol. Chem.* **286**, 37964–37975 (2011).
53. Turtle, C.J. *et al.* Innate signals overcome acquired TCR signaling pathway regulation and govern the fate of human CD161<sup>hi</sup> CD8 $\alpha$ <sup>+</sup> semi-invariant T cells. *Blood* **118**, 2752–2762 (2011).
54. Gérard, S. *et al.* Human iNKT and MAIT cells exhibit a PLZF-dependent proapoptotic propensity that is counterbalanced by XIAP. *Blood* **121**, 614–623 (2013).
55. Roederer, M., Nozzi, J.L. & Nason, M.C. SPICE: exploration and analysis of post-cytometric complex multivariate datasets. *Cytometry A* **79**, 167–174 (2011).



This work is licensed under the Creative Commons Attribution-NonCommercial-No Derivative Works 3.0 Unported License. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-nd/3.0/>